VERU INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
VERU INC. (VERU) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 114.70% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-10
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 114.70%, a 0.52% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 0.00%, a 100.00% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-12-31 was 116.60%, a 6.10% increase year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 115.30%, a 5.20% increase year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 114.57%, a 5.14% increase from fiscal 2024.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 108.97%, a 7.50% increase from fiscal 2023.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 101.37%.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2017 was 43.19%, a 0.00% change from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 114.70% 10-Q · filed 2026-08-10 | 115.00% 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-13 | 116.60% 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | 116.60% 10-Q · filed 2026-02-11 | |||||
| 2025-09-30 | 114.57% 10-K · filed 2025-12-17 | |||||
| 2025-06-30 | 115.30% 10-Q · filed 2026-08-10 | 114.60% 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 115.50% 10-Q · filed 2026-05-13 | 110.20% 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | 109.90% 10-Q · filed 2026-02-11 | |||||
| 2024-09-30 | 108.97% 10-K · filed 2025-12-17 | |||||
| 2024-06-30 | 109.60% 10-Q · filed 2025-08-12 | 109.64% 10-Q · filed 2024-08-08 | 108.90% 10-Q · filed 2025-08-12 | 108.86% 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 109.10% 10-Q · filed 2025-05-08 | 105.60% 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 104.00% 10-Q · filed 2025-02-13 | |||||
| 2023-09-30 | 101.37% 10-K · filed 2024-12-16 | |||||
| 2023-06-30 | 104.96% 10-Q · filed 2024-08-08 | 101.37% 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 102.90% 10-Q · filed 2023-05-11 | |||||
| 2022-06-30 | 92.58% 10-Q/A · filed 2023-11-15 | |||||
| 2022-03-31 | 76.12% 10-Q · filed 2023-05-11 | |||||
| 2017-09-30 | 43.19% 10-K · filed 2018-01-02 | |||||
| 2017-03-31 | 43.76% 10-Q · filed 2017-05-10 | |||||
| 2016-12-31 | 43.76% 10-Q · filed 2017-02-09 | |||||
| 2016-09-30 | 43.19% 10-K · filed 2016-12-12 | |||||
| 2016-06-30 | 43.19% 10-Q · filed 2016-07-28 | 43.19% 10-Q · filed 2016-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |